Quel est le prix pour Venus Medtech (Hangzhou) Inc. (2500)

Le prix pour Venus Medtech (Hangzhou) Inc. (2500) est $0.13048475

Quelle est la capitalisation boursière pour Venus Medtech (Hangzhou) Inc. (2500)

La capitalisation boursière pour Venus Medtech (Hangzhou) Inc. (2500) est $57.55M

Revenus de Venus Medtech (Hangzhou) Inc. (2500)

Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-Vitae, a balloon-expandable dry-tissue product; Venus-PowerX, a self-expanding dry-tissue product; Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation; Liwen RF, a radiofrequency ablation system for the treatment of hypertrophic cardiomyopathy; and renal artery denervation ablation system for the treatment of hypertension. In addition, the company offers procedural accessories comprising catheter sheath product and balloon catheter. Venus Medtech (Hangzhou) Inc. was incorporated in 2009 and is headquartered in Hangzhou, the People’s Republic of China.

Année	Revenus	Changez
Pas assez de données pour les dates fournies.

Année

Revenus

Changez

Pas assez de données pour les dates fournies.

Entreprise	Revenus	Différence de revenus	Pays
STERIS plc STE.US	$6.04B	-	IE
Shanghai United Imaging Healthcare Co., Ltd. 688271.SS	-	-	CN
Ypsomed Holding AG YPSN.SW	-	-	CH
Medacta Group S.A. MOVE.SW	-	-	CH
Jafron Biomedical Co.,Ltd. 300529.SZ	-	-	CN

Entreprise

Revenus

Différence de revenus

Pays